Optiscan Imaging (OIL) Q3 2026 TU earnings summary

Executive summary

• Lodged US FDA dossier for InSpecta®, advancing entry into the US veterinary market.

• Significant progress in clinical studies for InVue® and InForm® devices, supporting upcoming FDA submissions.

• Named finalist in two categories at the Endeavour Awards, highlighting innovation and leadership.

• Expanded clinical and regulatory teams to support increased activity and future growth.

Financial highlights

• R&D expenditure for the quarter was $1.672m, driving clinical and regulatory progress.

• Net cash outflow from operating activities was $2.421m for the quarter, mainly due to higher R&D spend.

• Receipts from customers totaled $153k for the quarter and $669k for the nine months.

• Cash and cash equivalents at quarter end were $15.126m, providing an estimated 6.2 quarters of funding.

• No new financing facilities drawn; $17.751m raised from equity in the nine months.

Outlook and guidance

• FDA submissions for InVue® and InForm® expected in the second half of 2026.

• Commercial launch of InSpecta® into the US veterinary market planned for later in 2026.

• US-based clinical studies at Mayo Clinic to commence in upcoming quarters.

• Cost efficiencies anticipated as foundational regulatory processes are leveraged for future products.